Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Azacitidine Plus Oxaliplatin in Recurrent and Metastatic EBV-Associated Gastric Cancer
KCT0007269Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Sep 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of azacitidine and oxaliplatin in gastric cancer (GC) and gastric adenocarcinoma, sponsored by Boryung. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
azacitidineoxaliplatin
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on KCT0007269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007269.